FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559375949> ?p ?o ?g. }

• W2559375949 abstract "Abstract The FCR regimen is the most active treatment program in CLL, with 72% of frontline patients achieving a complete remission (CR) lasting a median of 7 years. However, most patients are not cured and will eventually relapse with CLL. In order to evaluate how these patients should be subsequently managed, we analyzed our institutional experience with 300 patients treated with frontline FCR (Blood 112:975). After a median follow-up of 6 years, 116 patients (39%) had failed FCR therapy with 13 primary refractory disease and 103 relapses from partial remission (PR), nodular PR (nPR) or CR. Compared with patients in ongoing remission, relapsed/refractory patients had more adverse baseline characteristics including a greater proportion with performance status ≥ 1 (71% vs 53% p=0.002), elevated β2m (54% vs 36% p=0.002), white cell count ≥ 150 x 10^9/L (25% vs 12% p=0.003), unmutated IgVH (81% vs 44% p&lt;0.001) and ZAP-70 positivity (78% vs 49% p&lt;0.001). The aim of the current analysis was to determine the duration of survival (OS) following second-line therapy in 97 patients who had completed salvage treatment. The median follow-up was 32 (range 3 – 69) months, and the median OS (mOS) was 32 months. Characteristics associated with favorable OS were: (1) previous best response to FCR of nPR/CR lasting ≥ 18 months (mOS 47 months, vs 13 months for primary refractory disease, PR or nPR/CR lasting &lt;18 months p=0.002); (2) β2m &lt; 3.0 mg/L (mOS not reached, vs 17 months p=0.0003) and (3) platelets ≥ 100x10^9/L (mOS 47 months, vs 15 months p=0.004). Poor risk cytogenetic abnormalities were common at FCR failure: among 38 assessable patients, 7 (18%) had 17p- and 18 (47%) had 11q- by conventional karyotyping and/or FISH. Although patients with 17p- or 11q- had an inferior survival, this survival disadvantage was confined entirely to those who also had an elevated β2m ≥ 3.0 mg/L. Surprisingly, patients relapsing after durable FCR remissions (≥ 5 years) and patients with slowly progressive relapse (time to salvage ≥ 12 months after FCR failure) had similar OS as their more adverse counterparts (p=0.76 and 0.86 respectively). A prognostic model comprising β2m and platelet count effectively divided patients into low, intermediate and high risk categories with mOS of &gt;45, 32 and 13 months respectively (p&lt;0.0001). Patients received treatment chosen at the discretion of individual treating physicians and the CR rate of second-line therapy were: FCR (n=30), 17%; rituximab (n=25), 4%; alemtuzumab ± rituximab (n=16), 31%; FCR & alemtuzumab (CFAR, n=9), 56%; lymphoma-type chemotherapy (n=5), 0%; other treatment (n=12), 0%. The CR rate for CFAR was significantly higher than that of FCR (p=0.03), although the median remission duration (30 vs 20 months) and OS (44 vs 32 months) were similar (p=0.87 and 0.51 respectively). None of the regimens showed a significant survival benefit. Allogeneic stem cell transplantation (SCT) was performed in 27 (28%) patients at a median of 15 months after first salvage. Patients receiving SCT had a significantly superior OS than those who did not undergo SCT (not reached vs 30 months, p=0.03). Of the 14 patients surviving for more than four years, 11 (79%) had undergone a SCT. Patients who fail FCR therapy had high risk disease features including elevated β2m, unmutated IgVH and ZAP-70 positivity, and most had adverse cytogenetic findings at relapse. Results of salvage therapy in this group were poor with a median survival of less than three years. The majority of long-term survivors had received allogeneic stem cell transplantation." @default.
• W2559375949 created "2016-12-08" @default.
• W2559375949 creator A5011548707 @default.
• W2559375949 creator A5027575595 @default.
• W2559375949 creator A5033737136 @default.
• W2559375949 creator A5034517642 @default.
• W2559375949 creator A5035354255 @default.
• W2559375949 creator A5089428686 @default.
• W2559375949 creator A5090435894 @default.
• W2559375949 date "2008-11-16" @default.
• W2559375949 modified "2023-10-18" @default.
• W2559375949 title "Life after Fludarabine, Cyclophosphamide, & Rituximab (FCR) - the Clinical Outcome of Patients with Chronic Lymphocytic Leukemia Who Receive Salvage Treatment after Frontline FCR." @default.
• W2559375949 doi "https://doi.org/10.1182/blood.v112.11.2090.2090" @default.
• W2559375949 hasPublicationYear "2008" @default.
• W2559375949 type Work @default.
• W2559375949 sameAs 2559375949 @default.
• W2559375949 citedByCount "5" @default.
• W2559375949 countsByYear W25593759492013 @default.
• W2559375949 crossrefType "journal-article" @default.
• W2559375949 hasAuthorship W2559375949A5011548707 @default.
• W2559375949 hasAuthorship W2559375949A5027575595 @default.
• W2559375949 hasAuthorship W2559375949A5033737136 @default.
• W2559375949 hasAuthorship W2559375949A5034517642 @default.
• W2559375949 hasAuthorship W2559375949A5035354255 @default.
• W2559375949 hasAuthorship W2559375949A5089428686 @default.
• W2559375949 hasAuthorship W2559375949A5090435894 @default.
• W2559375949 hasConcept C121332964 @default.
• W2559375949 hasConcept C126322002 @default.
• W2559375949 hasConcept C141071460 @default.
• W2559375949 hasConcept C142424586 @default.
• W2559375949 hasConcept C197934379 @default.
• W2559375949 hasConcept C2776694085 @default.
• W2559375949 hasConcept C2776755627 @default.
• W2559375949 hasConcept C2777938653 @default.
• W2559375949 hasConcept C2778461978 @default.
• W2559375949 hasConcept C2779263901 @default.
• W2559375949 hasConcept C2779338263 @default.
• W2559375949 hasConcept C2780653079 @default.
• W2559375949 hasConcept C2780775027 @default.
• W2559375949 hasConcept C2781413609 @default.
• W2559375949 hasConcept C3018657049 @default.
• W2559375949 hasConcept C71924100 @default.
• W2559375949 hasConcept C87355193 @default.
• W2559375949 hasConcept C90924648 @default.
• W2559375949 hasConceptScore W2559375949C121332964 @default.
• W2559375949 hasConceptScore W2559375949C126322002 @default.
• W2559375949 hasConceptScore W2559375949C141071460 @default.
• W2559375949 hasConceptScore W2559375949C142424586 @default.
• W2559375949 hasConceptScore W2559375949C197934379 @default.
• W2559375949 hasConceptScore W2559375949C2776694085 @default.
• W2559375949 hasConceptScore W2559375949C2776755627 @default.
• W2559375949 hasConceptScore W2559375949C2777938653 @default.
• W2559375949 hasConceptScore W2559375949C2778461978 @default.
• W2559375949 hasConceptScore W2559375949C2779263901 @default.
• W2559375949 hasConceptScore W2559375949C2779338263 @default.
• W2559375949 hasConceptScore W2559375949C2780653079 @default.
• W2559375949 hasConceptScore W2559375949C2780775027 @default.
• W2559375949 hasConceptScore W2559375949C2781413609 @default.
• W2559375949 hasConceptScore W2559375949C3018657049 @default.
• W2559375949 hasConceptScore W2559375949C71924100 @default.
• W2559375949 hasConceptScore W2559375949C87355193 @default.
• W2559375949 hasConceptScore W2559375949C90924648 @default.
• W2559375949 hasLocation W25593759491 @default.
• W2559375949 hasOpenAccess W2559375949 @default.
• W2559375949 hasPrimaryLocation W25593759491 @default.
• W2559375949 hasRelatedWork W1965604253 @default.
• W2559375949 hasRelatedWork W1990815726 @default.
• W2559375949 hasRelatedWork W2047361930 @default.
• W2559375949 hasRelatedWork W2053682062 @default.
• W2559375949 hasRelatedWork W2085074066 @default.
• W2559375949 hasRelatedWork W2120141541 @default.
• W2559375949 hasRelatedWork W2142099365 @default.
• W2559375949 hasRelatedWork W2249215531 @default.
• W2559375949 hasRelatedWork W2348637346 @default.
• W2559375949 hasRelatedWork W2523669856 @default.
• W2559375949 hasRelatedWork W2556454004 @default.
• W2559375949 hasRelatedWork W2564158403 @default.
• W2559375949 hasRelatedWork W2570365985 @default.
• W2559375949 hasRelatedWork W2575619275 @default.
• W2559375949 hasRelatedWork W2588070030 @default.
• W2559375949 hasRelatedWork W2590154459 @default.
• W2559375949 hasRelatedWork W2810037575 @default.
• W2559375949 hasRelatedWork W3109434564 @default.
• W2559375949 hasRelatedWork W3131584132 @default.
• W2559375949 hasRelatedWork W3196771116 @default.
• W2559375949 isParatext "false" @default.
• W2559375949 isRetracted "false" @default.
• W2559375949 magId "2559375949" @default.
• W2559375949 workType "article" @default.